Loading
A phase 1/2 trial of PF-08634404, Ipilimumab, Axitinib in renal cell carcinoma, run by Pfizer, now recruiting.
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer is a phase 1/2 interventional study registered as NCT07227415 by Pfizer, with 224 participants planned, started 2026-02-10 and due to reach its primary completion in 2027-11-02. Interventions recorded: PF-08634404, Ipilimumab, Axitinib. Conditions listed: Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PF-08634404, Ipilimumab, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Shares PF-08634404, Pfizer (incl. Seagen).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/